Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

Documenti analoghi

• Budesonide, Added to PTCy‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation
  di: Piyanuch Kongtim, et al.
  Pubblicazione: (2025)
• Rapid HHV ‐6 Clearance Following Preemptive Short‐Course Foscarnet in Allogeneic Stem Cell Transplant Recipients
  di: Piyatida Chumnumsiriwath, et al.
  Pubblicazione: (2026)
• Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial
  di: Hannah Goulart, et al.
  Pubblicazione: (2025)
• Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
  di: Peiqi Liang, et al.
  Pubblicazione: (2024)
• Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis
  di: Rong Wang, et al.
  Pubblicazione: (2024)